| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.03 | 0.5 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | -0.044 | 0.5 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.5 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.031 | 0.5 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |